According to recent news reports, Sanofi-Aventis diabetes drug Acomplia could help to improve blood sugar control amongst patients suffering from type 2 diabetes who are failing to control their condition using insulin therapy.
Sanofi, a French pharmaceutical company, have defended the drug following rejection as a weight loss treatment in America. The Food and Drug Administration rejected the drug due to fears that it could provoke suicidal thoughts.
Acomplia has faced a rocky road after clinical trials apparently revealed increased likelihood of anxiety and depression as side effects from weight loss treatment. Sanofi, who had hoped that the drug would become a blockbuster, are now seeking to reposition it as a type 2 diabetes drug. Trial data show it could help diabetics to achieve their HbA1c goals.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Conversation about doctors’ appointments occurring virtually rumbles on

More than half of GP appointments are still being delivered remotely in…

Coronavirus: UK instructed to stay at home this weekend

Health Secretary Matt Hancock has said that staying at home this weekend…

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…